Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation

NATerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

G-CSF

"Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.~Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously."

DRUG

Leukapheresis

leukapheresis

DRUG

Busulfan

Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2

PROCEDURE

Stem cell reinfusion

autologous stem cell transplant

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ESP Pharma

UNKNOWN

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER